Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease

The Pharmacogenomics Journal
C E PattersonA P Passmore

Abstract

Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E ε4 (APOE ε4) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) ≥21) (P<0.01). In moderate-to-severe AD (MMSE ≤15), presence of the BCHE-K variant was associated with late response to cholinesterase inhibitor treatment (P=0.02). Testing for APOE and BCHE genotypes may be useful in therapeutic decision making.

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Sep 1, 1992·Journal of the American Geriatrics Society·T N Tombaugh, N J McIntyre
Feb 11, 1988·Nucleic Acids Research·S A MillerH F Polesky
Jan 1, 1987·Methods in Enzymology·K B Mullis, F A Faloona
Jul 30, 1982·Science·R T BartusA S Lippa
Sep 1, 1982·The American Journal of Psychiatry·B ReisbergT Crook
Jul 1, 1995·Journal of Geriatric Psychiatry and Neurology·J D NadlerF Plum
Aug 1, 1994·Journal of Neuroscience Methods·R CrookK Duff
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·J PoirierS Gauthier
Dec 16, 1996·Annals of the New York Academy of Sciences·M R FarlowS Hui
Oct 20, 1998·International Journal of Geriatric Psychiatry·S H MacGowanM Scott
Dec 24, 1998·Journal of Medical Genetics·P G KehoeM J Owen
Jul 10, 1999·Journal of Neurology·P K PanegyresB A Kakulas
Dec 22, 1999·Neurology·M R FarlowB Gulanski
Jul 25, 2000·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A S RigaudF Boller
Dec 28, 2000·Acta Neurologica Scandinavica·A Alvarez-ArcayaN Peña
Feb 15, 2001·Dementia and Geriatric Cognitive Disorders·J AerssensW Parys
Aug 15, 2001·Neurology·B WinbladUNKNOWN Donepezil Nordic Study Group
Apr 2, 2003·Pharmacogenetics·Kirsty K O'BrienIan G McKeith
Jan 4, 2005·Dementia and Geriatric Cognitive Disorders·Pieter Jelle VisserUNKNOWN Dutch ENA-NL-01 Study Group
Apr 19, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·C HolmesD Warden
Jun 25, 2005·Current Alzheimer Research·Clive G BallardSultan Darvesh
Aug 17, 2005·Dementia and Geriatric Cognitive Disorders·A BizzarroC Masullo
Dec 20, 2005·Lancet·Cleusa P FerriUNKNOWN Alzheimer's Disease International

❮ Previous
Next ❯

Citations

Jun 2, 2011·European Journal of Clinical Pharmacology·Caterina ChianellaSilvia Fuselli
May 14, 2014·Annual Review of Neuroscience·Jin-Tai YuJohn Hardy
Apr 24, 2013·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Stephan SchwartzmanMaurício Torres
Feb 25, 2020·Current Alzheimer Research·Marta KowalskaJolanta Dorszewska
Jun 15, 2019·Current Alzheimer Research·Chung-Hsien LinKuen-Cheh Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.